Abstract
Type 2 diabetes patients are at high risk for macrovascular complications and suffer from very high cardiovascular mortality.Recent trials have demonstrated that agents in two antidiabetic classes (SGLT2 inhibitors and GLP-1 receptor agonists) are able to reduce cardiovascular complications in diabetics. People have forgotten that very similar evidence is available also in an older preparation - pioglitazone, which can retard the atherosclerotic process and reduce cardiovascular events.
Piogltazone is an insulin sensitizer, that causes durable improvement of metabolic control and multiple components of metabolic syndrome including non-alcoholic fatty liver disease. Treatment with pioglitazone is acompanied by some adverse effects but is still usable in the treatment schema in type 2 diabetic patients.